Exact Mass: 317.0899

N2-Monodes-methylnizatidine

C11H19N5O2S2 (317.098)

N2-Monodes-methylnizatidine is a metabolite of nizatidine. Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid. (Wikipedia)

N-2-Mdmn

C11H19N5O2S2 (317.098)

buxifoliadine-H

C16H15NO6 (317.0899)

6-Hydroxy-3-ketostauranthine

C16H15NO6 (317.0899)

Maybridge4_003884

C14H14F3NO4 (317.0875)

Maybridge4_003929

C13H14F3N3O3 (317.0987)

2-{2-[4-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]hydrazono}-2-(methylsulfonyl)acetonitrile

C14H15N5O2S (317.0946)

CHEMBL3637854

C17H16ClNO3 (317.0819)

8-hydroxylycorin-7-one

C16H15NO6 (317.0899)

Polyoxin C

C11H15N3O8 (317.0859)

schumannificine

C16H15NO6 (317.0899)

Citramine

C16H15NO6 (317.0899)

Puberuline F

C16H15NO6 (317.0899)

9(10H)-Acridinone, 1,4,5-trihydroxy-3,6-dimethoxy-10-methyl-

C16H15NO6 (317.0899)

1, 3, 5-trihydroxy-2, 4-dimethoxy-10-methyl-10H-acridin-9-one|citruscridone

C16H15NO6 (317.0899)

2,3-dimethoxy-1,4,5-trihydroxy-10-methylacridone

C16H15NO6 (317.0899)

2,3-Dimethoxy-10-methyl-1,5,6-trihydroxyacridin-9(10H)-one

C16H15NO6 (317.0899)

Methoxydianthramide M

C16H15NO6 (317.0899)

1,3,6-trihydroxy-4,5-dimethoxy-10-methylacridin-9-one

C16H15NO6 (317.0899)

MMV676431

C17H16NO3Cl (317.0819)

Desmethylnizatidine

C11H19N5O2S2 (317.098)

3-O-Methylrimiterol sulfate

C13H19NO6S (317.0933)

5,6-Dihydro-8,9-dimethoxypyrrolo[2,1-a]isoquinoline-2,3-dicarboxylic acid

C16H15NO6 (317.0899)

atalafoline B

C16H15NO6 (317.0899)

5-[(3,5-dimethoxybenzoyl)amino]-2-hydroxybenzoic acid

C16H15NO6 (317.0899)

1-(4-(4-Nitro-3-(trifluoromethyl)phenyl)piperazin-1-yl)ethanone

C13H14F3N3O3 (317.0987)

Methyl 4-(4-(Bis(2-Chloroethyl)Amino)Phenyl)Butyrate

C15H21Cl2NO2 (317.0949)

N-Dipropyldopamine hydrobromide

C14H24BrNO2 (317.099)

Benzoic acid, 4-[(3,5-dimethoxybenzoyl)amino]-2-hydroxy-

C16H15NO6 (317.0899)

tert-butyl 4-[4-(chloromethyl)-1,3-thiazol-2-yl]piperazine-1-carboxylate

C13H20ClN3O2S (317.0965)

4-(3-METHOXYPROPYL)-5-[4-(TRIFLUOROMETHYL)PHENYL]-4H-1,2,4-TRIAZOLE-3-THIOL

C13H14F3N3OS (317.081)

3-(4-Chlorophenyl)-3-(2-phenylacetamido)propanoic acid

C17H16ClNO3 (317.0819)

1,7-DIPHENYL-1H-PYRIMIDO[4,5-D][1,3]OXAZINE-2,4-DIONE

C18H11N3O3 (317.08)

Methyl 4-benzyloxy-5-methoxy-2-nitrobenzoate

C16H15NO6 (317.0899)

Valdecoxib-d3

C16H11D3N2O3S (317.0913)

Methyl 5-(benzyloxy)-4-methoxy-2-nitrobenzoate

C16H15NO6 (317.0899)

sodium 1-benzyl-5-phenylbarbiturate

C17H14N2NaO3 (317.0902)

6-methoxy-N-(4-methoxyphenyl)quinazolin-4-amine,hydrochloride

C16H16ClN3O2 (317.0931)

N-[(3S)-1-Chloro-5-methyl-2-oxohexan-3-yl]-4-methylbenzene-1-sulfonamide

C14H20ClNO3S (317.0852)

4-Amino-2-(phenacylthio)-5-pyrimidinecarboxylic acid ethyl ester

C15H15N3O3S (317.0834)

Buxifoliadine H

C16H15NO6 (317.0899)

4-Sulfonamide-[4-(thiomethylaminobutane)]benzamide

C12H19N3O3S2 (317.0868)

(4-Methylphenyl)-(10-phenothiazinyl)methanone

C20H15NOS (317.0874)

N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)thio]acetamide

C15H15N3O3S (317.0834)

1-[4-[2-Nitro-4-(trifluoromethyl)phenyl]piperazin-1-yl]ethanone

C13H14F3N3O3 (317.0987)

2-Chlorobenzyl 4-(propionylamino)benzoate

C17H16ClNO3 (317.0819)

N-(6-chloro-2,3-dihydro-1,4-benzodioxin-7-yl)-3-phenylpropanamide

C17H16ClNO3 (317.0819)

methyl 5-[(E)-3-(2-chlorophenyl)prop-2-enoyl]-2,4-dimethyl-1H-pyrrole-3-carboxylate

C17H16ClNO3 (317.0819)

methyl 5-[(E)-3-(3-chlorophenyl)prop-2-enoyl]-2,4-dimethyl-1H-pyrrole-3-carboxylate

C17H16ClNO3 (317.0819)

4-Chloro-2-[[oxo-(4-propan-2-ylphenyl)methyl]amino]benzoic acid

C17H16ClNO3 (317.0819)

5-C-glycyl uridine

C11H15N3O8 (317.0859)

(5S)-5-((1R)-1-Amino-2-oxo-2-hydroxyethyl)uridine

C11H15N3O8 (317.0859)

N-(3-chloro-4-methylphenyl)-2-[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]acetamide

C17H16ClNO3 (317.0819)

N-Desmethylnizatidine

C11H19N5O2S2 (317.098)

LY456236

C16H16ClN3O2 (317.0931)

LY456236 is a selective, non-competitive and orally active mGlu1 receptor antagonist that inhibits phosphoinositide hydrolysis with an IC50 of 0.145 μM. LY456236 also inhibits EGFR with an IC50 of 0.91 μM[1][3].

atalafoline b

C16H15NO6 (317.0899)

{"Ingredient_id": "HBIN017264","Ingredient_name": "atalafoline b","Alias": "NA","Ingredient_formula": "C16H15NO6","Ingredient_Smile": "CN1C2=C(C=CC(=C2O)OC)C(=O)C3=C1C(=C(C=C3O)OC)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1954","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

2-{[hydroxy(2-hydroxy-4-methoxyphenyl)methylidene]amino}-4-methoxybenzoic acid

C16H15NO6 (317.0899)

1,5-dihydroxy-2,3,4-trimethoxy-10h-acridin-9-one

C16H15NO6 (317.0899)

5-hydroxy-n-[2-hydroxy-4-(methoxycarbonyl)phenyl]-2-methoxybenzenecarboximidic acid

C16H15NO6 (317.0899)

1,3,6-trihydroxy-2,5-dimethoxy-10-methylacridin-9-one

C16H15NO6 (317.0899)

(12r,13s,18s)-8,12,14-trihydroxy-4-methyl-3,11-dioxa-15-azatetracyclo[8.8.0.0²,⁷.0¹³,¹⁸]octadeca-1,4,7,9,14-pentaen-6-one

C16H15NO6 (317.0899)

(s)-amino[(2r,3s,4r,5r)-3,4-dihydroxy-5-[4-hydroxy-5-(hydroxymethyl)-2-oxopyrimidin-1-yl]oxolan-2-yl]acetic acid

C11H15N3O8 (317.0859)

8,12,14-trihydroxy-4-methyl-3,11-dioxa-15-azatetracyclo[8.8.0.0²,⁷.0¹³,¹⁸]octadeca-1,4,7,9,14-pentaen-6-one

C16H15NO6 (317.0899)

amino({3,4-dihydroxy-5-[4-hydroxy-5-(hydroxymethyl)-2-oxopyrimidin-1-yl]oxolan-2-yl})acetic acid

C11H15N3O8 (317.0859)

1,5,6-trihydroxy-2,3-dimethoxy-10-methylacridin-9-one

C16H15NO6 (317.0899)

2-hydroxy-4,4,9-trimethyl-3,12,14-trioxa-9-azatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1(17),6,10,15-tetraene-5,8-dione

C16H15NO6 (317.0899)